argenex (ARGX) Competitors

argenex has a net margin of 32.19% compared to Gilead Sciences' net margin of -10.64%. argenex's return on equity of 43.59% beat Gilead Sciences' return on equity.

In the previous week, Gilead Sciences had 39 more articles in the media than argenex. MarketBeat recorded 55 mentions for Gilead Sciences and 16 mentions for argenex. Gilead Sciences' average media sentiment score of 1.23 beat argenex's score of 0.51 indicating that Gilead Sciences is being referred to more favorably in the news media.

Gilead Sciences has higher revenue and earnings than argenex. Gilead Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

argenex has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Gilead Sciences has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

60.3% of argenex shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 0.3% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

argenex presently has a consensus target price of $1,158.61, indicating a potential upside of 12.14%. Gilead Sciences has a consensus target price of $158.04, indicating a potential upside of 4.67%. Given argenex's stronger consensus rating and higher probable upside, equities research analysts clearly believe argenex is more favorable than Gilead Sciences.

Vertex Pharmaceuticals presently has a consensus price target of $569.52, indicating a potential upside of 4.29%. argenex has a consensus price target of $1,158.61, indicating a potential upside of 12.14%. Given argenex's higher possible upside, analysts clearly believe argenex is more favorable than Vertex Pharmaceuticals.

In the previous week, Vertex Pharmaceuticals had 11 more articles in the media than argenex. MarketBeat recorded 27 mentions for Vertex Pharmaceuticals and 16 mentions for argenex. Vertex Pharmaceuticals' average media sentiment score of 1.38 beat argenex's score of 0.51 indicating that Vertex Pharmaceuticals is being referred to more favorably in the media.

Vertex Pharmaceuticals has higher revenue and earnings than argenex. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Vertex Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

Vertex Pharmaceuticals has a net margin of 35.00% compared to argenex's net margin of 32.19%. argenex's return on equity of 43.59% beat Vertex Pharmaceuticals' return on equity.

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Regeneron Pharmaceuticals had 35 more articles in the media than argenex. MarketBeat recorded 51 mentions for Regeneron Pharmaceuticals and 16 mentions for argenex. Regeneron Pharmaceuticals' average media sentiment score of 0.66 beat argenex's score of 0.51 indicating that Regeneron Pharmaceuticals is being referred to more favorably in the media.

Regeneron Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, argenex has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

Regeneron Pharmaceuticals currently has a consensus target price of $800.36, indicating a potential downside of 3.31%. argenex has a consensus target price of $1,158.61, indicating a potential upside of 12.14%. Given argenex's stronger consensus rating and higher probable upside, analysts plainly believe argenex is more favorable than Regeneron Pharmaceuticals.

83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.3% of argenex shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 2.4% of argenex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Regeneron Pharmaceuticals has higher revenue and earnings than argenex. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

argenex has a net margin of 32.19% compared to Regeneron Pharmaceuticals' net margin of 27.86%. argenex's return on equity of 43.59% beat Regeneron Pharmaceuticals' return on equity.

75.3% of Moderna shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Moderna has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, argenex has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

argenex has a net margin of 32.19% compared to Moderna's net margin of -141.43%. argenex's return on equity of 43.59% beat Moderna's return on equity.

In the previous week, Moderna had 58 more articles in the media than argenex. MarketBeat recorded 74 mentions for Moderna and 16 mentions for argenex. Moderna's average media sentiment score of 0.53 beat argenex's score of 0.51 indicating that Moderna is being referred to more favorably in the media.

argenex has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Moderna currently has a consensus price target of $76.72, indicating a potential downside of 47.29%. argenex has a consensus price target of $1,158.61, indicating a potential upside of 12.14%. Given argenex's stronger consensus rating and higher probable upside, analysts plainly believe argenex is more favorable than Moderna.